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Alzheimer’s disease (AD)affectsmore than5millionAmer-
icans of all ages, and this number is projected to nearly triple to
more than 13 million by 2050 [1]. The prevalence among US
veterans is 563,786 individuals, similar to the overall popula-
tion, and is likewise expected to increase dramatically in the
coming decades [2–5]. Yet, there are concerns that the
number of at-risk veterans extends beyond the issues of popu-
lation aging. Notably, the prevalence of dementia in veterans
is predicted to rise as a result of an increasing incidence of trau-ccess article under the CC BY-NC-ND license (http://
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(PTSD) [2].
SinceMarch 2003, more than 2.3 million soldiers were de-
ployed to the Iraq-Afghanistan war zones [3], and among
these service members, nearly 300,000 veterans between
2000 and 2013 have been diagnosed with TBI [4] and more
than 83,000 with newly diagnosed PTSD [5]. As a result of
greatly improved military health and battlefield survival
from these signature acute injuries, there is now a paradox
that veterans will be at a greater risk of developing chronic
neurodegenerative diseases such as AD and dementia [2].2. Costs of dementia care
The aggregate cost of care for older adult individuals
affected by AD and other dementia is estimated to be
approximately $203 billion in direct and indirect expenses
[6]. Medicare and Medicaid cover approximately 70% of
these costs, but out-of-pocket expenses account for $34
billion or 17% of this total. Moreover, in 2008, the total
per-person payments from all sources of health care andeserved.
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pocket payments, were three times greater for Medicare ben-
eficiaries with a form of dementia than for other Medicare
beneficiaries when matched for age [7].
These costs reflect that people living with AD and other
dementia have more than three times the number of hospital
stays per year than other individuals of the same or similar
age [7]. Furthermore, they reflect the high costs associated
with long-term care services. For example, in 2012, the na-
tional average cost for a private room in a nursing home was
$90,520 per year and the average cost of an adult day center
was $70 per day [8]. These figures do not take into account
the number of or the dollar value of hours of unpaid care pro-
vided by nonprofessional and family caregivers. In 2012, the
total value of unpaid care provided by such individuals was
approximately $216 billion [6].
Dementia care is expensive today, and such related ex-
penditures are projected to increase dramatically. It is esti-
mated that aggregate payments for health care, long-term
care, and hospice will increase from the current $203 billion
to $1.2 trillion by 2050 [6]. However, what remains un-
known is how these costs will be affected by present and
future veterans who may be diagnosed with neurodegenera-
tive illnesses at an earlier than expected time points, possibly
in their fifth or even fourth decade of life.
Veterans with dementia incur elevated health-care costs.
They are more likely to require hospitalization and their hos-
pital stays tend to be substantially longer than those without
dementia [5]. In addition, possible risk factors for dementia
such as TBI and PTSD are also linked to substantially
increased health-care expenses. For example, one study found
that the median annual health-care costs for veterans diag-
nosed with TBI are four times higher than those for veterans
without TBI and are even higher for veterans experiencing
both TBI and PTSD or pain [9]. Psychiatric visits are also
much more common among veterans with dementia [2].
The annual cost of informal care provided to elderly
community-dwelling individuals with dementia, including
veterans, averaged approximately $18,385 per individual ac-
cording to a study conducted in 1998 [10]. These informal
costs, as well as the costs associated with nursing home
and home health care, are expected to increase dramatically
for veterans in the coming decade in line with expected
increases in the general population [11]. It is unknown if
veterans today or in the future will experience increased
care-related costs due to battle-related injuries (e.g., TBI
and PTSD) or whether the Veterans Health Administration
system will enable better care management for concomitant
diseases described in greater detail in Section 3.3. Are veterans at an increased risk of AD?
Military personnel and veterans are subject to the same
risk factors of AD as the general population, in addition to
potential exposure to other factors that may further increase
their risk. In the general population, there are hints in litera-ture of possible factors that increase an individual’s risk of
AD, including age, family history, and heart health. These
factors are outlined in greater detail in the following para-
graph. More research into how these factors may affect vet-
erans or military personnel is needed.
Age is the greatest risk factor for AD, with the incidence
of AD dementia doubling every 5 to 6 years after the age of
65 years [12]. Genetic factors may also increase the risk of
developing AD. The apolipoprotein E ε4 (APOE ε4) allele
is the strongest genetic predictor of risk for AD. Individuals
who inherit two copies of this allele have a 12- to 15-fold
increased risk of developing AD and an earlier age of onset
than individuals with other allelic forms of the APOE gene
[13]. Furthermore, TBI recovery and outcomes have been
connected to the possible genetic areas of interest, including
APOE ε4 (described previously). TBI in the presence of
APOE ε4 allele is associated with poorer health outcomes
in adults and is linked to increased mortality after ischemic
stroke and cardiopulmonary arrest [14,15]. Other genes have
also been linked to an increased risk of disease, including
genes involved in the processing of the AD precursor
protein and pathways involved in the immune response
and inflammation, lipid transport, synaptic function, and
other important physiologic processes that are involved in
AD pathogenesis [16]. The influence of genetics is also re-
flected in the fact that individuals with a parent or sibling
with AD are more likely to develop AD than those who do
not have a first-degree relative with AD [17].
Cardiovascular risk factors also raise the risk of dementia.
For example, in a study of 678 Catholic nuns, stroke
emerged as the greatest risk factor for subsequent dementia
[18], and other studies have linked an increase in dementia
incidence to hypertension [19], diabetes and insulin resis-
tance [20], obesity [21], and atherosclerosis [22].
Depression has also shown to increase the risk of demen-
tia [23], as do TBI and PTSD [2]. In addition, lifestyle fac-
tors including physical activity, smoking, diet, level of
education, and social and cognitive engagement and socio-
demographic factors such as race, gender, and socioeco-
nomic status may potentially be related to an increased
risk of dementia [24,25]. These factors impact the general
population; research regarding how these factors may
impact veterans and military personnel specifically is
needed to understand the potential risk to these groups.
In addition to the factors described in the above sections,
veterans may be at an increased risk for AD because of both
the demographics of the veteran population, compared with
the general population, and the risks related to combat in-
juries. Veterans are, on average, older than nonveterans
[26]. In Veterans aged 30 to 64 years, there is a higher pro-
portion of African-Americans compared to the overall US
population (16% -17% African American veterans
compared with 13% in the US population), and the incidence
of AD in African-Americans is about twice that of Caucasian
individuals [27]. Veterans may also be affected by socioeco-
nomic factors such as lower incomes or unemployment [28].
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tury wars includes more frequent and longer deployments
and increased exposure to hostile forces, suicide bombs,
and injured civilians, which may also link to an increased
risk of AD and related dementia [29].
Combat-related injuries include an increased incidence of
TBI and PTSD. TBI and PTSD are often referred to as
“invisible wounds of war” because those affected may
appear uninjured [30]. Research about these combat injuries
goes back at least to the First World War in which soldiers
exposed to trench warfare experienced symptoms then
described as “shell shock” or battle fatigue [27]. Both TBI
and PTSD have also been linked to an increased risk of
AD and related dementia, although the exact mechanisms
of this connection are unknown [31].3.1. TBI—potential risk factor
TBI is the most frequent cause of death and disability
among Americans under the age of 35 years, most frequently
as a result of automobile accidents, falls, and sports-related
injuries [28]. It occurs when an external force to the head
causes injury and results in an alteration or loss of conscious-
ness. Those with moderate and severe, but not mild, head in-
juries have a two- to fourfold increased risk of AD and other
dementias in late life [32].
The association of TBI with dementia has been reported
in both veteran and nonveteran populations. In the 1920s, de-
mentia pugilistica, now referred to as chronic traumatic en-
cephalopathy (CTE), was seen in boxers [33] and is
identified today in correlation to other sport activities
including American football, hockey, and other contact
sports. Sports-related TBI, particularly concussion, is a
frequent occurrence with 1.6 to 3.8 million affected annually
in the United States [34–36]. In military and veteran
populations, the widespread use of improvised explosive
devices in Iraq and Afghanistan reportedly produced up to
23% confirmed cases of TBI in one brigade combat team
of nearly 4000 soldiers [35]. This increase is further sup-
ported by estimates from the Defense and Veterans Brain
Injury Center that 22% of all combat wounds from the
wars in Afghanistan and Iraq are brain injuries compared
with 12% of combat wounds that occurred in Vietnam.
Multiple concussions or even a single moderate-to-severe
TBI can predispose individuals to develop a pathologically
distinct form of tauopathy-related dementia at an early age
[37]. Tauopathies are neurodegenerative diseases, such as
AD, characterized by neurofibrillary tangles comprised of
filamentous tau protein. In the early stages of CTE, large de-
posits of phosphorylated tau (phospho-tau) are seen, partic-
ularly in the frontal cortex. This pattern of phospho-tau
deposition is different from the pattern seen in AD. The
link between phospho-tau deposition in individuals with
TBI and neurodegenerative pathology is not well under-
stood; however, TBI could conceivably prompt multiple mo-
lecular pathways that result in the overproduction andaggregation of numerous key proteins that form the patho-
logic accumulations seen in neurodegenerative diseases
[38]. Clinically, CTE may cause alterations in an individ-
ual’s behavior/mood and/or an individual’s cognition [39].3.2. PTSD—potential risk factor
PTSD is a distinct psychological condition that often co-
occurs with TBI but may also occur in the absence of a brain
injury in response to emotionally upsetting events. The preva-
lence of PTSD in veterans is much higher than that seen in the
general population (13%–31% in veterans compared with 7%
in the US general population) [40], and those with PTSD are
also at nearly twice the risk of developing dementia [41,42].
The underlying mechanisms involved in PTSD are
believed to include changes in synaptic connectivity associ-
ated with learning and alterations of central and peripheral
hormones [43]. Veterans with PTSD have been shown to
have reduced hippocampal volume, correlating with
impaired memory [44]. Interestingly, PTSD is also associ-
ated with a greater risk of other comorbid conditions that
have been independently linked to an increased risk of de-
mentia. For example, a meta-analysis found that 52% of in-
dividuals with PTSD also had co-occurring major depressive
disorder, with higher rates among those with PTSD resulting
from military service [45]. Veterans with depression and
dysthymia are at twice the risk of developing dementia
compared with those without depression and dysthymia
[46]. Another study of veterans found that those with
PTSD had a 59% increased risk of coronary atherosclerosis
as measured by coronary artery calcification [47]. PTSD also
has been linked to a significant increased risk of prediabetes
and type 2 diabetes (odds ratio, 3.56) [48]. Greater under-
standing of how PTSD may contribute to an increased risk
of AD, as well as the comorbid conditions, is needed.4. Possible prevention of AD
To date, there is no treatment that stops or slows the pro-
gression of AD. However, there are numerous clinical
studies underway to develop and test therapies that may
inhibit or decelerate the progression of AD in individuals ex-
hibiting the early stages of the disease. One example is the
Dominantly Inherited Alzheimer’s Network Trial. This
study is enrolling adult children of individuals who have
rare genetic mutations in the genes for the amyloid precursor
protein (APP), presenilin 1 (PSEN1), or presenilin 2
(PSEN2), all of which cause early-onset autosomal-domi-
nant AD [49]. Other studies aimed at stopping or slowing
the progression of AD in its early stages among individuals
at a potential increased risk (based on genetics or altered bio-
logical markers associated with AD) have also recently
begun enrolling volunteers. These include the Alzheimer’s
Prevention Initiative studies [50], Anti-Amyloid Treatment
in Asymptomatic Alzheimer’s Disease (A4) study [51],
and TOMMORROW trial in AD [52]. These efforts are vital
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selection, and moving the field to a new era of improved
treatments to stop or slow disease progression.5. Responding to a growing crisis in the military
The links between risks factors, such as TBI and PTSD, and
AD are critical to the mental health of the USmilitary popula-
tion. Themilitary has responded to this growing threat in mul-
tiple ways. The Militarily-Relevant, Peer Reviewed
Alzheimer’s Disease Program (MRPRA) was created through
the Telemedicine & Advanced Technology Research Center
(TATRC) [53]. The mission of the MRPRA is to build an inte-
grated program devoted to understanding the association be-
tween TBI and AD and to reduce the burden on those
affected byTBIAD symptoms, especially in themilitary com-
munity. In its first years, the program focused on imaging, ge-
nomics, and proteomics, enhancing quality of life and tau
pathology. Another project, theVietnamVeteransAlzheimer’s
DiseaseNeuroimaging Initiative Project fundedby theDepart-
ment of Defense (DoD-ADNI) has been added to the overall
Alzheimer’s Disease Neuroimaging Initiative (ADNI) project
in an effort to determine the effects of TBI and PTSD on AD.
By assessingVietnamWarveterans between the ages of 60and
80 years, this study is attempting to use neuroimaging and
other biomarkers to establish biological connections between
TBI, PTSD, and AD. For example, a set of various proteins
synthesized within neurons is presently being assessed as po-
tential biomarkers, including glial fibrillary acidic protein,
neuron-specific enolase, myelin basic protein, and S100B
[54]. These ongoing studies may be able to identify whether
changes in these markers are able to function as diagnostic
and prognostic tools and predictors of adverse secondary ef-
fects that may assist in the diagnosis and management of TBI.6. Next steps
This review summarizes the current knowledge of
military-related costs, prevalence, and risks related to AD
and dementia and outlines ongoing efforts to increase our
understanding of AD in military-relevant populations (e.g.,
DoD-ADNI). Continued funding of the MRPRA through
TATRC will help us understand the basis for the relation-
ships that research has suggested and clarify the extent to
which military risk factors increase the risk of AD and
related dementia. In times of fiscal austerity, funding models
are increasingly incorporating partnership models to fund
longitudinal studies in older individuals that will provide
the necessary information for how and when dementia de-
velops as we age. The ADNI-DoD project is one example
that encourages the sharing of data and findings with the
global research community. This example sets the stage
for leveraging existing research explorations for further
study and highlights the need to study longitudinal change
in populations with potentially increased risk such as mili-
tary personnel and/or veterans to ascertain the degree ofrisk. To this end, the Global Alzheimer’s Association Inter-
active Network connects international data sets through a
federated network, allowing researchers around the globe
to query data to drive hypotheses, generate validation sam-
ples, and integrate complex computer modeling of disease-
disease or disease-risk interactions. Collaborations across
funding organizations may create opportunities to explore
including integrated analysis across the ADNI-DoD and
ADNI along with other TBI or PTSD and AD data sets, as
well as bridge longitudinal data sets associated with different
neurologic diseases such as Parkinson’s disease and AD
(e.g., Biomarkers Across Neurodegenerative Diseases fund-
ing announcement; alz.org/BAND).
Our understanding of the molecular mechanisms driving
the association of TBI and PTSD with AD is limited, and
more research is needed to elucidate these connections. This
knowledgewill not only add to our understanding of the path-
ogenic mechanisms that underlie neurodegeneration in gen-
eral but will also further aid in efforts to discover and
validate biomarkers thatmay better predict neurodegeneration
after either TBI or PTSD and to the development of a measure
to capture TBI exposure upon the initial injury. Broader efforts
in the AD research community will inform our understanding
of the linkage between TBI and PTSD with AD; however,
funding mechanisms to enable such explorations are impor-
tant both to leverage existing data sets and to integrate these
with the ongoing and novel data collection efforts.
There are clear gaps in our knowledge regarding
dementia-related health expenditures for veterans and the
population of current military personnel and veterans who
may be at a greater risk for developing AD and related de-
mentia in the future. Addressing these knowledge gaps at
all levels (molecular to economic) is essential for the
growing number of veterans who may develop dementia as
a result of military exposures. Moreover, the knowledge
gained will have ramifications throughout the society by
improving our understanding of the factors that contri-
bute to an increased incidence of dementia in an aging
population.References
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